Abstract: The present invention describes a method for identification of areas of a sample from which nucleic acid molecules originate using labeling of said nucleic acid molecules by two-dimensionally distributed oligonucleotide markers. Further analysis of hybrids between the nucleic acid molecules and the oligonucleotide markers allow identification of the original position of the labelled nucleic acid molecules in the sample.
Type:
Application
Filed:
April 3, 2013
Publication date:
March 12, 2015
Applicant:
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
Inventors:
Aleksey Soldatov, Tatiana Borodina, Hans Lehrach
Abstract: This invention relates to methods for the evaluation and/or quantification of the binding affinity of small molecules or other compounds to target components contained within an analyte, such as target proteins contained within the proteome of a cell or tissue.
Type:
Grant
Filed:
September 26, 2008
Date of Patent:
February 24, 2015
Assignee:
Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
Inventors:
Henrik Daub, Michaela Bairlein, Kirti Sharma, Klaus Godl, Andreas Tebbe, Christoph Weber
Abstract: The present invention relates to novel peptides capable of binding to action. The peptides are useful in methods for detecting actin in vitro or in living cells.
Type:
Grant
Filed:
November 27, 2008
Date of Patent:
February 17, 2015
Assignee:
Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
Inventors:
Roland Wedlich-Söldner, Michael Sixt, Julia Riedl, Alvaro Crevenna
Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.
Type:
Grant
Filed:
January 18, 2011
Date of Patent:
February 17, 2015
Assignees:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of Massachusetts
Inventors:
Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
Type:
Grant
Filed:
January 6, 2010
Date of Patent:
January 13, 2015
Assignees:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of Massachusetts
Inventors:
Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
Type:
Grant
Filed:
October 4, 2010
Date of Patent:
November 25, 2014
Assignees:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of Massachusetts
Inventors:
Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
Type:
Grant
Filed:
December 21, 2012
Date of Patent:
November 25, 2014
Assignees:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of Massachusetts
Inventors:
Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
Abstract: The present invention is directed to a method for preparing an expression vector encoding a tailored recombinase, wherein said tailored recombinase recombines asymmetric target sites within the LTR of proviral DNA of a retrovirus inserted into the genome of a host cell and is useful as means for excising the provirus from the genome of the host cell. The present invention further relates to an in vitro-method of optimising the treatment of a retroviral infection of a subject and to the use of tailored recombinases for the preparation of pharmaceutical compositions for reducing the viral load in a subjected infected by a retrovirus.
Type:
Grant
Filed:
January 3, 2008
Date of Patent:
October 28, 2014
Assignees:
Technische Universität Dresden, Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Heinrich-Pette-Institut für Experimentelle Virologie und Immunologie an der Universität Hamburg
Inventors:
Joachim Hauber, Frank Buchholz, Ilona Hauber, Francis A Stewart, Indrani Sarkar
Abstract: The method comprises fabricating a layer stack on a substrate, the layer stack comprising at least two electrically conducting layers and at least one electrically insulating layer arranged between the two electrically conducting layers, and displacing a first portion of the layer stack away from its original position, the first portion comprising an edge portion of the layer stack, and bending the first portion back towards a second portion of the layer stack. The bending may comprise a rolling-up of the first portion of the layer stack.
Type:
Grant
Filed:
February 15, 2012
Date of Patent:
October 14, 2014
Assignee:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
Abstract: The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either Fc?RIIb or Fc?RIIa.
Type:
Grant
Filed:
November 26, 2004
Date of Patent:
October 7, 2014
Assignee:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
Inventors:
Robert Huber, Peter Sondermann, Uwe Jacob, Kerstin Wendt, Chiara Cabrele, Luis Moroder
Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
Type:
Grant
Filed:
December 2, 2009
Date of Patent:
October 7, 2014
Assignees:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of Massachusetts
Inventors:
Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
Abstract: A copolymer containing, in addition to recurring elements of a sulfonated poly(arylene) containing exclusively recurring structural element(s) of the general formulas —[—Ar1(SO3M)n-X—]— and —[—Ar2(SO3M)n-Y—]—, wherein X and Y, which are identical or different from each other, each represent an electron-acceptor group, Ar1 and Ar2, which are either identical or different from each other, represent an aromatic or heteroaromatic ring system with 5-18 ring atoms; wherein the aromatic or heteroaromatic ring system, in addition to the SO3M and the substituents X and Y, optionally comprises additional substituents which are not electron-donor groups; M represents monovalent cation and n is an integral number between 1 and 4; and wherein X, Y, Ar1, Ar2, M and n can be identical or different in various structural elements, independently of each other, one or several additional elements of at least one additional monomer or macromonomer.
Type:
Grant
Filed:
November 16, 2012
Date of Patent:
September 30, 2014
Assignee:
Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
Inventors:
Michael Schuster, Klaus-Dieter Kreuer, Henrik Thalbitzer Andersen, Joachim Maier
Abstract: The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to a selective CDK9 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with a selective CDK9 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to a selective CDK9 inhibitor, whereby the patient is suspected to suffer from NUT midline carcinoma (NMC). The present invention also relates to a method of monitoring or predicting the efficacy of a treatment of NUT midline carcinoma (NMC), wherein treatment with a selective CDK9 inhibitor is in particular envisaged. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one rearrangement in the NUT gene for screening and/or validation of a medicament for the treatment NUT midline carcinoma (NMC) is described.
Type:
Application
Filed:
August 22, 2012
Publication date:
September 25, 2014
Applicants:
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LEAD DISCOVERY CENTER GmbH
Inventors:
Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
Abstract: The invention concerns a method for separating a racemic compound-forming chiral substance by a cyclic crystallization process which is conducted in at least one first crystallization unit (10) and in at least one second crystallization unit (18), wherein in a first process cycle an enantiomer is crystallized in the first crystallization unit (10) and a racemic compound is crystallized in the second crystallization unit (18), wherein in a second process cycle the enantiomer is crystallized in the second crystallization unit (18) and the racemic compound is crystallized in the first crystallization unit (10), wherein during each process cycle in at least one process sub-step (B?C, F?G) a mother liquor (12) being contained in the first crystallization unit (10) is mutually exchanged with a mother liquor (20) being contained in the second crystallization unit (18). An auto-seeding process sub-step is applied at the beginning of a process cycle.
Type:
Grant
Filed:
February 8, 2012
Date of Patent:
September 2, 2014
Assignee:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
Inventors:
Heike Lorenz, Daniel Polenske, Linzhu Klukas, Andreas Seidel-Morgenstern
Abstract: Boron-comprising perylene monoimides and a process for producing the boron-comprising perylene monoimides are provided. The boron-comprising perylene monoimides are useful as building blocks for producing perylene monoimide derivatives and monoimide derivatives. The boron-comprising perylene monoimides are also useful for preparing dye-sensitized solar cells.
Type:
Grant
Filed:
August 5, 2013
Date of Patent:
August 26, 2014
Assignees:
BASF SE, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
Inventors:
Henrike Wonneberger, Ingmar Bruder, Robert Send, Glauco Battagliarin, Chen Li, Klaus Muellen
Abstract: The present invention relates to the total chemical synthesis of the monosaccharide 35# (R??H), the disaccharide 36# (R??H; R??H), the trisaccharide 37# (R??H; R??H; R???H) and the tetrasaccharide 1# (R??H; R??H; R???H) of the following general formula wherein R represents —Y—NH2Y represents a linker R? is H or R? is H or R?? is H or of the lipopolysaccharide from Neisseria meningitidis, as well as to the trisaccharide 37# and the tetrasaccharide 1#, to vaccines containing at least one of the saccharides 1#, 35#, 36#, and 37# and to the use of such vaccine for immunization against diseases caused by infection with bacteria containing the tetrasaccharide ?-GlcNAc-(1?2)-?-Hep-(1?3)-?-Hep-(1?5)-?-Kdo or the trisaccharide ?-Hep-(1?3)-?-Hep-(1?5)-?-Kdo or ?-GlcNAc-(1?2)-?-Hep-(1?3)-?-Hep, especially for immunization against meningitis, septicaemia, pneumonia and nasopharyngitis caused by Neisseria meningitidis.
Type:
Application
Filed:
September 24, 2012
Publication date:
August 21, 2014
Applicant:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
Inventors:
Peter H. Seeberger, You Yang, Chakkumkal Anish, Anika Reinhardt
Abstract: According to the invention, a computer-implemented method for processing digital stereo image content, comprises the steps of estimating a perceived disparity of the stereo image content and processing the stereo image content, based on the estimated perceived disparity.
Type:
Application
Filed:
May 18, 2012
Publication date:
August 7, 2014
Applicants:
Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V, UNIVERSITAT DES SAARLANDES
Inventors:
Piotr Didyk, Tobias Ritschel, Elmar Eisemann, Karol Myszkowski, Hans-Peter Seidel
Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
Type:
Grant
Filed:
June 21, 2010
Date of Patent:
August 5, 2014
Assignees:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of Massachusetts
Inventors:
Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
Abstract: A method and device for efficiently simulating lens flares produced by an optical system is provided. The method comprises the steps of—Simulating paths of rays from a light source through the optical system, the rays representing light; and Estimating, for points in a sensor plane, an irradiance, based on intersections of the simulated paths with the sensor plane.
Type:
Application
Filed:
April 29, 2011
Publication date:
July 31, 2014
Applicants:
UNIVERSITAT DES SAARLANDES, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.
Inventors:
Matthias Hullin, Sungkil Lee, Hans-Peter Seidel, Elmar Eisemann